Not Yet Recruiting PHASE4 INTERVENTIONAL 2-arm NCT06311916

Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.

Efficacy and Safety of Neoadjuvant HAIC Combined With Immunotherapy and Targeted Therapy in Patients With Resectable Intermediate-stage HCC Screened by a Multimodal Deep Learning Model: a Multicenter Randomized Controlled Trial.

Sponsor: Chen Xiaoping

Conditions HCC

Interventions HAIC + Tirelizumab +lenvatinib +liver resection liver resection

Updated 3 times since 2024 Last updated: Mar 9, 2024 Started: May 1, 2024 Primary completion: Dec 31, 2027 Completion: Dec 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates HCC and is currently actively recruiting participants. Chen Xiaoping leads this study, which shows 3 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE4
Apr 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chen Xiaoping

Data source: Tongji Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.